Evidence map›Paper›PMID 32101721›Full record

ArticleTrends in cancer2020

On Epigenetic Plasticity and Genome Topology.

Charalampos Lazaris, Iannis Aifantis, Aristotelis Tsirigos

Open access · greenAbstract read
In one paragraph

Article in Trends in cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Epigenetics of Muscle- and Brain-Specific Expression of KLHL Family Genes.International journal of molecular sciences · 2020
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Charalampos LazarisDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA. Electronic address: lazaris@wi.mit.edu.
Iannis AifantisDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Aristotelis TsirigosDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Applied Bioinformatics Laboratories, Office of Science & Research, New York University School of Medicine, New York, NY 10016, USA.
New York University · USOffice of Science · US

Funding

The impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jane Amanda Skok · 2019 to 2026
$17.0M
Role of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3M
The role of the SCF/FBW7 ubiquitin ligase complex in hematopiesis and leukemia.R01CA133379 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2009 to 2018
$3.6M
The cohesin complex as a tumor suppressor in myeloid leukemiaR01CA216421 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2017 to 2021
$2.5M
Mechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5M
Mapping cancer micro-environments for acute leukemiaR01CA202025 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, SCHWAB, SUSAN RUTH · 2016 to 2020
$2.3M
Long non-coding RNAs in hematopoiesis and blood malignancyR01CA194923 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2015 to 2019
$2.3M
Mechanisms of T cell leukemia induction and maintenanceR01CA149655 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2010 to 2015
$2.0M
NCI NIH HHS P01 CA229086NCI NIH HHS R01 CA133379NCI NIH HHS R01 CA149655NCI NIH HHS R01 CA173636NCI NIH HHS R01 CA194923NCI NIH HHS R01 CA202025NCI NIH HHS R01 CA216421NCI NIH HHS R01 CA228135
6 · The paper itself

Abstract

Mounting evidence links genetic lesions with genome topology alterations and aberrant gene activation. However, the role of epigenetic plasticity remains elusive. Emerging studies implicate DNA methylation, transcriptional elongation, long noncoding RNAs (lncRNAs), and CCCTC-binding factor (CTCF)-RNA interactions, but systematic approaches are needed to fully decipher the role of epigenetic plasticity in genome integrity and function.

Indexed as

EpigenomicsGene Expression Regulation, NeoplasticGenome, HumanCell Transformation, NeoplasticChromatinHumansModels, GeneticNeoplasmsOncogenesTranscription, GeneticChromatincancerepigenetic plasticitygenome organizationTAD boundariestopologically associating domains (TADs)transcriptional dysregulation

Identifiers

PMID32101721
PMCPMC10027362
OpenAlexW3004799820

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.